

Ciara C O'sullivan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/511914/publications.pdf>

Version: 2024-02-01

24
papers

900
citations

566801

15
h-index

610482

24
g-index

24
all docs

24
docs citations

24
times ranked

1847
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210920.	1.5	5
2	Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2021, 188, 477-487.	1.1	5
3	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	1.1	8
4	Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care. <i>European Journal of Cancer</i> , 2021, 159, 38-51.	1.3	34
5	Evolving standards of care and new challenges in the management of HER2-positive breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 355-374.	157.7	77
6	Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 695-706.	1.1	19
7	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	0.8	251
8	The emerging role of CDK4/6i in HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988766.	1.4	25
9	Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 294-299.	2.3	13
10	Updates in the Evaluation and Management of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 794-807.	1.4	39
11	Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?. <i>Current Oncology Reports</i> , 2018, 20, 63.	1.8	2
12	Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 173-182.	0.5	26
13	A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2017, 22, 888.	1.9	3
14	Current challenges in the management of breast cancer brain metastases. <i>Seminars in Oncology</i> , 2017, 44, 85-100.	0.8	44
15	ANG1005 for breast cancer brain metastases: correlation between 18F-FLT PET after first cycle and MRI in response assessment. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 51-59.	1.1	27
16	Pharmacodynamic markers and clinical results from the phase 2 study of the <sc>SMAC</sc> mimetic birinapant in women with relapsed platinum-resistant or refractory epithelial ovarian cancer. <i>Cancer</i> , 2016, 122, 588-597.	2.0	77
17	CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1657-1667.	0.9	11
18	Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer. <i>Oncologist</i> , 2016, 21, 523-526.	1.9	22

#	ARTICLE	IF	CITATIONS
19	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 235-251.	1.1	18
20	Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. <i>Frontiers in Oncology</i> , 2014, 4, 42.	1.3	76
21	The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1291-1297.	1.8	89
22	Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 169-182.	0.5	15
23	Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 779-790.	1.4	12
24	Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 382-5.	0.3	2